characterizing the two main types of polyglandular autoimmunity (APS1 and APS2) 2, 3 identified hypoparathyroidism as occurring only in the context of APS1, there have been occasional case reports of idiopathic hypoparathyroidism occurring with other autoimmune disorders. 4 The first attempt to identify parathyroid autoantibodies as markers for autoimmune hypoparathyroidism used an indirect immunofluorescence assay and found that these were present in 38% of patients with idiopathic hypoparathyroidism, 26% of patients with idiopathic
Addison's disease, 12% of patients with Hashimoto's thyroiditis and 6% of controls. 5 Hypoparathyroid individuals also had a higher than expected frequency of adrenal, thyroid or gastric parietal cell autoantibodies. In another early assay using dispersed human parathyroid cells, eight of 23 sera from patients with idiopathic hypoparathyroidism reacted by immunofluorescence; two of the positive sera came from patients who had APS1, but the other 6 were from adults, 2 of whom also had thyroid or adrenal autoantibodies. 6 On the other hand, a recent study of 87 patients with idiopathic hypoparathyroidism found no increase in the prevalence of thyroid autoimmunity in these individuals. 7 Thyroid autoimmunity is the commonest of the organ-specific autoimmune disorders and would be expected to be more prevalent if autoimmune hypoparathyroidism behaves as most organ-specific autoimmune conditions by clustering with these other disorders.
However, this was a small series and it is possible that only a proportion of patients might have had an autoimmune basis for their hypoparathyroidism: only these would be expected to show an increase in the prevalence of other autoimmune conditions such as thyroid disease.
Continued research has defined two parathyroid autoantigens so far: the calcium-sensing receptor (CaSR) and NACHT leucine-richrepeat protein 5 (NALP5). Autoantibodies against the CaSR have been identified in both APS1 patients and in patients with idiopathic hypoparathyroidism, occurring as either as a solitary disorder or in association with other autoimmune diseases such as thyroid autoimmunity. [8] [9] [10] [11] [12] They have a specificity and sensitivity of 83% and 50%, respectively, in relation to autoimmune hypoparathyroidism in APS1. 12 In contrast, NALP5 autoantibodies appear to be confined to patients with APS1 and have a specificity and a sensitivity of 100% and 49%
for autoimmune hypoparathyroidism in APS1, respectively; one adultonset case of hypoparathyroidism with these autoantibodies turned out to have occult APS1. 13, 14 In view of the uncertainty over the possible association of auto- The numbers of patients are given with percentages in parentheses.
| MATERIALS AND METHODS

| Patients
T A B L E 1 Summary of APS patient demographics and autoimmune diseases 57 female), who had no clinical signs and no personal or family history of autoimmune, endocrine or tumour diseases, served as controls.
| Measurement of autoantibodies
Immunoprecipitation assays for detecting CaSR autoantibodies in patient and control sera were carried out as previously detailed. 17 Anti-NALP5 autoantibodies were detected in radioligand binding assays, which are detailed elsewhere. 13 Autoantibodies against interleukin (IL)-22, IL-17A, IL-17F, and interferon (IFN)-ω, IFN-α2A and IFN-λ1 were detected in enzyme-linked immunosorbent assays (ELISA). 18, 19 All sera were tested in duplicate at least twice, and autoantibody levels expressed as an antibody index. [17] [18] [19] The upper limit of normal for each assay was calculated using the mean antibody index + 3SD of 80 healthy individuals. [17] [18] [19] Any serum with an antibody index above the upper limit of normal was designated as autoantibody-positive. For all assays, intra-and interassay coefficients of variation were below 8% and 12%, respectively.
| Analysis of AIRE gene mutations
DNA was extracted from 1 mL of patient EDTA-collected blood using 
| RESULTS
| Analysis of patients with autoimmune polyglandular syndrome
The autoimmune polyglandular syndromes identified were APS2 in 28 patients, APS3 in 125 patients and APS4 in 25 patients (Table 1) .
A summary of patient demographic data and the presence of endocrine and nonendocrine diseases is given in Table 1 . Three patients (F6, S102 and S122) were diagnosed with hypoparathyroidism, all having parathyroid hormone (PTH) levels below the lower limit of normal ( Table 2 ). One of these three patients had APS3, and the other two were diagnosed with APS4 ( Table 2 ). None of the three patients was positive for autoantibodies against the CaSR, NALP5 or cytokines IL-22, IL-17A, IL-17F, IFN-α2A, IFN-ω and IFN-λ1 (Table 2) .
| CaSR and NALP5 autoantibody prevalence in patients and controls
Four patients (2.2%), but none of the controls, were positive for CaSR autoantibodies ( Figure 1A ; Table 2 ). Three of these four patients had APS3, and the other had APS2 (Table 2) . Three patients showed normal serum calcium, while one patient showed below normal levels (Table 2) . Serum phosphate levels were below normal in three of the four patients ( Table 2 ). One of the four patients had a PTH level above the upper limit of normal ( Table 2 ). None of the 178 patients or 80 controls was positive for NALP5 autoantibodies ( Figure 1B ).
| Cytokine autoantibody prevalence in patients and controls
Of 178 The cytokine autoantibody-positive patients were nine with APS3
and two with APS4 (Table 2) . One patient with IFN-α2A autoantibodies had late-onset myasthenia gravis as part of their APS4 diagnosis including autoimmune thyroid disease, ocular myasthenia and primary hypogonadism ( Table 2) . Of the eight patients with cytokine autoantibodies, but no CaSR autoantibodies, all had serum calcium levels within the range of normal, three had serum phosphate concentrations below the normal lower limit and two had PTH levels above the upper limit of normal (Table 2 ).
| Association of CaSR and cytokine autoantibodies
The three APS3 patient samples positive for CaSR autoantibodies were also positive for autoantibodies against two to five different cytokines; all three samples were positive for autoantibodies against IL-17 and IL-22, while two also had IFN autoantibodies (Table 2 ). In the fourth sample, from a patient with APS2, no cytokine autoantibodies were detectable (Table 2) . Eight patient samples (6 with APS3 and 2 with APS4) without CaSR autoantibodies were positive for autoantibodies against a single cytokine ( Table 2 ). The association of cytokine autoantibodies with CaSR autoantibodies was significant (P = .0007, Fisher's exact test).
| AIRE gene mutations
As the presence of cytokine autoantibodies in 11 patients (Table 2) indicated the possibility of occult APS1 in these individuals, we went on to sequence their AIRE gene to look for potential mutations. DNA was available for all 11 patients except for S20 and S117 (Table 2) . However, no known or novel mutations were found in any of the samples tested. 
| DISCUSSION
The original purpose of this study was to determine whether CaSR or NALP5 autoantibodies could be detected in patients with APS2, 3 or 4 as markers of an associated parathyroid autoimmune process.
The finding of a low prevalence (2.2%) of CaSR autoantibodies indicates that parathyroid autoimmunity is an uncommon component of these adult-onset polyglandular syndromes, in contrast to APS1, and that even when CaSR autoantibodies are present, clinical disease did not result in this series of patients. Indeed, hypoparathyroidism was clinically present in only three patients. Our results also confirm that NALP5 autoantibodies are restricted to APS1. 13, 14 To be confident that these CaSR autoantibody-positive patients truly had APS2 or 3, we undertook further studies using analysis of cytokine autoantibodies to exclude APS1, as there are reports describing atypical clinical cases of APS1. [21] [22] [23] Notably, heterozygous mutations F I G U R E 1 Detection of CaSR, NALP5 and cytokine autoantibodies in APS2, APS3 and APS4 patients and healthy controls. As detailed in Section 2, patient and control sera were evaluated for CaSR, NALP5 and cytokine autoantibodies using immunoprecipitation assays, radioligand binding assays and ELISA, respectively. The antibody index is shown for each APS2 (n = 28), APS3 (n = 125) and APS4 (n = 25) patient, and each healthy control (n = 80), and is the mean of at least two experiments. Three of the four samples positive for CaSR autoantibodies were positive for multiple cytokine autoantibodies; in addition, eight other patients were positive for autoantibodies against a single, or in one case, two cytokines. As these autoantibodies strengthened the possibility of APS1 in these patients, we undertook sequence analysis of the 14 AIRE gene exons, including exon 8 which is the location of the recently described mutations in the PHD1 zinc finger, 24 but did not detect any mutations in those positive for cytokine autoantibodies.
Our results indicate that 6.2% of patients with APS2, 3 or 4 had at least one cytokine autoantibody. Of these, there appears to be a group in whom there is subclinical autoantibody evidence of parathyroid autoimmunity that is associated with autoantibodies against multiple cytokines and a further group with more isolated cytokine autoantibodies, but no CaSR autoantibodies. There were no other clinical features that appeared to distinguish between those with solitary and those with multiple cytokine autoantibodies. Only one other study has looked at a similarly large set of non-APS1 patients;
in 354 patients with Addison's disease, in isolated form or in association with APS2, one sample was positive IFN-ω autoantibodies but other cytokine autoantibodies were not examined. 16 Meloni et al 15 found no IFN-α2 or IFN-ω autoantibodies in 27 patients with APS2, and IL-17 and IL-22 autoantibodies have only previously been examined in 21 patients with APS2, in whom there were no positive results. 18 One of our patients who had IFN-α2A autoantibodies had myasthenia gravis which is known to be associated with cytokine autoantibodies. 26 Our results are possibly related to the large sample size and the inclusion of APS3 and APS4 patients as well as those with APS2.
In summary, we describe the presence of CaSR autoantibodies in 2.2% of patients with APS2, 3 or 4 indicating a very low level of subclinical parathyroid autoimmunity in these syndromes. What prevents the development of clinical hypoparathyroidism is unclear, although it is well-known that thyroid autoantibodies, for instance, are very common in the absence of progression to overt hypothyroidism. In addition, we have found that 6.2% of these patients had autoantibodies against cytokines, which are normally associated exclusively with APS1, and yet we could detect no AIRE gene mutations. Autoantibodies against cytokines therefore constitute a previously unrecognized, albeit an uncommon feature of non-APS1 polyglandular autoimmunity.
